Gene therapy for osteoarthritis

Pharmacokinetics of intra-articular self-complementary adeno-associated virus interleukin-1 receptor antagonist delivery in an equine model

Rachael S. Watson Levings, Ted A. Broome, Andrew D. Smith, Brett L. Rice, Eric P. Gibbs, David A. Myara, E. Viktoria Hyddmark, Elham Nasri, Ali Zarezadeh, Padraic P. Levings, Yuan Lu, Margaret E. White, E. Anthony Dacanay, Gregory B. Foremny, Christopher H Evans, Alison J. Morton, Mathew Winter, Michael J. Dark, David M. Nickerson, Patrick T. Colahan & 1 others Steven C. Ghivizzani

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Toward the treatment of osteoarthritis (OA), the authors have been investigating self-complementary adeno-associated virus (scAAV) for intra-articular delivery of therapeutic gene products. As OA frequently affects weight-bearing joints, pharmacokinetic studies of scAAV gene delivery were performed in the joints of the equine forelimb to identify parameters relevant to clinical translation in humans. Using interleukin-1 receptor antagonist (IL-1Ra) as a secreted therapeutic reporter, scAAV vector plasmids containing codon-optimized cDNA for equine IL-1Ra (eqIL-1Ra) were generated, which produced eqIL-1Ra at levels 30-to 50-fold higher than the native sequence. The most efficient cDNA was packaged in AAV2.5 capsid, and following characterization in vitro, the virus was injected into the carpal and metacarpophalangeal joints of horses over a 100-fold dose range. A putative ceiling dose of 5 × 1012 viral genomes was identified that elevated the steady-state eqIL-1Ra in the synovial fluids of injected joints by >40-fold over endogenous levels and was sustained for at least 6 months. No adverse effects were seen, and eqIL-1Ra in serum and urine remained at background levels throughout. Using the 5 × 1012 viral genome dose of scAAV, and green fluorescent protein as a cytologic marker, the local and systemic distribution of vector and transduced cells following intra-articular injection scAAV.GFP were compared in healthy equine joints and in those with late-stage, naturally occurring OA. In both cases, 99.7% of the vector remained within the injected joint. Strikingly, the pathologies characteristic of OA (synovitis, osteophyte formation, and cartilage erosion) were associated with a substantial increase in transgenic expression relative to tissues in healthy joints. This was most notable in regions of articular cartilage with visible damage, where foci of brilliantly fluorescent chondrocytes were observed. Overall, these data suggest that AAV-mediated gene transfer can provide relatively safe, sustained protein drug delivery to joints of human proportions.

Original languageEnglish (US)
Pages (from-to)90-100
Number of pages11
JournalHuman Gene Therapy Clinical Development
Volume29
Issue number2
DOIs
StatePublished - Jun 1 2018

Fingerprint

Dependovirus
Interleukin-1 Receptors
Osteoarthritis
Genetic Therapy
Horses
Pharmacokinetics
Joints
Interleukin 1 Receptor Antagonist Protein
Viral Genome
Complementary DNA
Carpal Joints
Genes
Osteophyte
Intra-Articular Injections
Synovitis
Forelimb
Capsid
Synovial Fluid
Weight-Bearing
Articular Cartilage

Keywords

  • AAV
  • arthritis
  • gene therapy
  • IL-1Ra
  • osteoarthritis
  • pharmacokinetics

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Gene therapy for osteoarthritis : Pharmacokinetics of intra-articular self-complementary adeno-associated virus interleukin-1 receptor antagonist delivery in an equine model. / Watson Levings, Rachael S.; Broome, Ted A.; Smith, Andrew D.; Rice, Brett L.; Gibbs, Eric P.; Myara, David A.; Hyddmark, E. Viktoria; Nasri, Elham; Zarezadeh, Ali; Levings, Padraic P.; Lu, Yuan; White, Margaret E.; Dacanay, E. Anthony; Foremny, Gregory B.; Evans, Christopher H; Morton, Alison J.; Winter, Mathew; Dark, Michael J.; Nickerson, David M.; Colahan, Patrick T.; Ghivizzani, Steven C.

In: Human Gene Therapy Clinical Development, Vol. 29, No. 2, 01.06.2018, p. 90-100.

Research output: Contribution to journalArticle

Watson Levings, RS, Broome, TA, Smith, AD, Rice, BL, Gibbs, EP, Myara, DA, Hyddmark, EV, Nasri, E, Zarezadeh, A, Levings, PP, Lu, Y, White, ME, Dacanay, EA, Foremny, GB, Evans, CH, Morton, AJ, Winter, M, Dark, MJ, Nickerson, DM, Colahan, PT & Ghivizzani, SC 2018, 'Gene therapy for osteoarthritis: Pharmacokinetics of intra-articular self-complementary adeno-associated virus interleukin-1 receptor antagonist delivery in an equine model', Human Gene Therapy Clinical Development, vol. 29, no. 2, pp. 90-100. https://doi.org/10.1089/humc.2017.142
Watson Levings, Rachael S. ; Broome, Ted A. ; Smith, Andrew D. ; Rice, Brett L. ; Gibbs, Eric P. ; Myara, David A. ; Hyddmark, E. Viktoria ; Nasri, Elham ; Zarezadeh, Ali ; Levings, Padraic P. ; Lu, Yuan ; White, Margaret E. ; Dacanay, E. Anthony ; Foremny, Gregory B. ; Evans, Christopher H ; Morton, Alison J. ; Winter, Mathew ; Dark, Michael J. ; Nickerson, David M. ; Colahan, Patrick T. ; Ghivizzani, Steven C. / Gene therapy for osteoarthritis : Pharmacokinetics of intra-articular self-complementary adeno-associated virus interleukin-1 receptor antagonist delivery in an equine model. In: Human Gene Therapy Clinical Development. 2018 ; Vol. 29, No. 2. pp. 90-100.
@article{b3cc1c1b083e4028b75b5901abf2db0d,
title = "Gene therapy for osteoarthritis: Pharmacokinetics of intra-articular self-complementary adeno-associated virus interleukin-1 receptor antagonist delivery in an equine model",
abstract = "Toward the treatment of osteoarthritis (OA), the authors have been investigating self-complementary adeno-associated virus (scAAV) for intra-articular delivery of therapeutic gene products. As OA frequently affects weight-bearing joints, pharmacokinetic studies of scAAV gene delivery were performed in the joints of the equine forelimb to identify parameters relevant to clinical translation in humans. Using interleukin-1 receptor antagonist (IL-1Ra) as a secreted therapeutic reporter, scAAV vector plasmids containing codon-optimized cDNA for equine IL-1Ra (eqIL-1Ra) were generated, which produced eqIL-1Ra at levels 30-to 50-fold higher than the native sequence. The most efficient cDNA was packaged in AAV2.5 capsid, and following characterization in vitro, the virus was injected into the carpal and metacarpophalangeal joints of horses over a 100-fold dose range. A putative ceiling dose of 5 × 1012 viral genomes was identified that elevated the steady-state eqIL-1Ra in the synovial fluids of injected joints by >40-fold over endogenous levels and was sustained for at least 6 months. No adverse effects were seen, and eqIL-1Ra in serum and urine remained at background levels throughout. Using the 5 × 1012 viral genome dose of scAAV, and green fluorescent protein as a cytologic marker, the local and systemic distribution of vector and transduced cells following intra-articular injection scAAV.GFP were compared in healthy equine joints and in those with late-stage, naturally occurring OA. In both cases, 99.7{\%} of the vector remained within the injected joint. Strikingly, the pathologies characteristic of OA (synovitis, osteophyte formation, and cartilage erosion) were associated with a substantial increase in transgenic expression relative to tissues in healthy joints. This was most notable in regions of articular cartilage with visible damage, where foci of brilliantly fluorescent chondrocytes were observed. Overall, these data suggest that AAV-mediated gene transfer can provide relatively safe, sustained protein drug delivery to joints of human proportions.",
keywords = "AAV, arthritis, gene therapy, IL-1Ra, osteoarthritis, pharmacokinetics",
author = "{Watson Levings}, {Rachael S.} and Broome, {Ted A.} and Smith, {Andrew D.} and Rice, {Brett L.} and Gibbs, {Eric P.} and Myara, {David A.} and Hyddmark, {E. Viktoria} and Elham Nasri and Ali Zarezadeh and Levings, {Padraic P.} and Yuan Lu and White, {Margaret E.} and Dacanay, {E. Anthony} and Foremny, {Gregory B.} and Evans, {Christopher H} and Morton, {Alison J.} and Mathew Winter and Dark, {Michael J.} and Nickerson, {David M.} and Colahan, {Patrick T.} and Ghivizzani, {Steven C.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1089/humc.2017.142",
language = "English (US)",
volume = "29",
pages = "90--100",
journal = "Human gene therapy. Clinical development",
issn = "2324-8637",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Gene therapy for osteoarthritis

T2 - Pharmacokinetics of intra-articular self-complementary adeno-associated virus interleukin-1 receptor antagonist delivery in an equine model

AU - Watson Levings, Rachael S.

AU - Broome, Ted A.

AU - Smith, Andrew D.

AU - Rice, Brett L.

AU - Gibbs, Eric P.

AU - Myara, David A.

AU - Hyddmark, E. Viktoria

AU - Nasri, Elham

AU - Zarezadeh, Ali

AU - Levings, Padraic P.

AU - Lu, Yuan

AU - White, Margaret E.

AU - Dacanay, E. Anthony

AU - Foremny, Gregory B.

AU - Evans, Christopher H

AU - Morton, Alison J.

AU - Winter, Mathew

AU - Dark, Michael J.

AU - Nickerson, David M.

AU - Colahan, Patrick T.

AU - Ghivizzani, Steven C.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Toward the treatment of osteoarthritis (OA), the authors have been investigating self-complementary adeno-associated virus (scAAV) for intra-articular delivery of therapeutic gene products. As OA frequently affects weight-bearing joints, pharmacokinetic studies of scAAV gene delivery were performed in the joints of the equine forelimb to identify parameters relevant to clinical translation in humans. Using interleukin-1 receptor antagonist (IL-1Ra) as a secreted therapeutic reporter, scAAV vector plasmids containing codon-optimized cDNA for equine IL-1Ra (eqIL-1Ra) were generated, which produced eqIL-1Ra at levels 30-to 50-fold higher than the native sequence. The most efficient cDNA was packaged in AAV2.5 capsid, and following characterization in vitro, the virus was injected into the carpal and metacarpophalangeal joints of horses over a 100-fold dose range. A putative ceiling dose of 5 × 1012 viral genomes was identified that elevated the steady-state eqIL-1Ra in the synovial fluids of injected joints by >40-fold over endogenous levels and was sustained for at least 6 months. No adverse effects were seen, and eqIL-1Ra in serum and urine remained at background levels throughout. Using the 5 × 1012 viral genome dose of scAAV, and green fluorescent protein as a cytologic marker, the local and systemic distribution of vector and transduced cells following intra-articular injection scAAV.GFP were compared in healthy equine joints and in those with late-stage, naturally occurring OA. In both cases, 99.7% of the vector remained within the injected joint. Strikingly, the pathologies characteristic of OA (synovitis, osteophyte formation, and cartilage erosion) were associated with a substantial increase in transgenic expression relative to tissues in healthy joints. This was most notable in regions of articular cartilage with visible damage, where foci of brilliantly fluorescent chondrocytes were observed. Overall, these data suggest that AAV-mediated gene transfer can provide relatively safe, sustained protein drug delivery to joints of human proportions.

AB - Toward the treatment of osteoarthritis (OA), the authors have been investigating self-complementary adeno-associated virus (scAAV) for intra-articular delivery of therapeutic gene products. As OA frequently affects weight-bearing joints, pharmacokinetic studies of scAAV gene delivery were performed in the joints of the equine forelimb to identify parameters relevant to clinical translation in humans. Using interleukin-1 receptor antagonist (IL-1Ra) as a secreted therapeutic reporter, scAAV vector plasmids containing codon-optimized cDNA for equine IL-1Ra (eqIL-1Ra) were generated, which produced eqIL-1Ra at levels 30-to 50-fold higher than the native sequence. The most efficient cDNA was packaged in AAV2.5 capsid, and following characterization in vitro, the virus was injected into the carpal and metacarpophalangeal joints of horses over a 100-fold dose range. A putative ceiling dose of 5 × 1012 viral genomes was identified that elevated the steady-state eqIL-1Ra in the synovial fluids of injected joints by >40-fold over endogenous levels and was sustained for at least 6 months. No adverse effects were seen, and eqIL-1Ra in serum and urine remained at background levels throughout. Using the 5 × 1012 viral genome dose of scAAV, and green fluorescent protein as a cytologic marker, the local and systemic distribution of vector and transduced cells following intra-articular injection scAAV.GFP were compared in healthy equine joints and in those with late-stage, naturally occurring OA. In both cases, 99.7% of the vector remained within the injected joint. Strikingly, the pathologies characteristic of OA (synovitis, osteophyte formation, and cartilage erosion) were associated with a substantial increase in transgenic expression relative to tissues in healthy joints. This was most notable in regions of articular cartilage with visible damage, where foci of brilliantly fluorescent chondrocytes were observed. Overall, these data suggest that AAV-mediated gene transfer can provide relatively safe, sustained protein drug delivery to joints of human proportions.

KW - AAV

KW - arthritis

KW - gene therapy

KW - IL-1Ra

KW - osteoarthritis

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=85049150030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049150030&partnerID=8YFLogxK

U2 - 10.1089/humc.2017.142

DO - 10.1089/humc.2017.142

M3 - Article

VL - 29

SP - 90

EP - 100

JO - Human gene therapy. Clinical development

JF - Human gene therapy. Clinical development

SN - 2324-8637

IS - 2

ER -